Santa Cruz is a small coastal city, the kind of place where the surfers outnumber the office workers and the bookstores still sell hand-printed zines. So it tracks, weirdly, that it became one of the first cities in the United States to formally pull back the policing of psilocybin mushrooms, ayahuasca, and peyote. The city council voted unanimously to make personal use, possession, and cultivation of natural psychedelics among the lowest priorities for local law enforcement.

That single vote — quiet, unflashy, passed in a council chamber most people will never set foot in — said something larger about where the country is heading on plant medicine and master plants. Ayahuasca, psilocybin, San Pedro, peyote: substances that have been used ceremonially for centuries are being reconsidered as legitimate tools for addiction recovery, treatment-resistant depression, and the kind of stuck-life patterns that ordinary therapy sometimes can't budge.

If you've been quietly researching a retreat, or wondering whether the legal landscape is shifting fast enough to matter, this is the kind of decision worth understanding. Not because Santa Cruz is going to be your destination — but because it tells you something about the direction of travel.

What the Santa Cruz Resolution Actually Says

The resolution doesn't legalize anything. That's the first thing worth being clear about. What it does is instruct local police to deprioritize investigations and arrests of adults 21 and over who are using, possessing, or growing entheogenic plants and fungi for personal use. Commercial activity — selling, trafficking — is still on the table for enforcement.

The list of covered substances is specifically natural: psilocybin mushrooms, ayahuasca, peyote, ibogaine-containing plants, and other plant or fungal preparations with psychoactive compounds. Synthetic compounds like LSD and MDMA aren't included, which is consistent with how Denver and Oakland framed their earlier moves. The distinction matters because the case for decriminalization here leans heavily on the idea that these are traditional medicines with deep cultural lineage, not lab inventions.

What does that mean on the ground? Practically, it means a Santa Cruz resident growing a few mushroom jars in their closet is unlikely to face local prosecution. It does not mean they can legally sell them, advertise them, or operate a retreat center. Federal law also still classifies psilocybin and DMT (the active alkaloid in ayahuasca) as Schedule I, so the federal picture hasn't budged.

Why Cities Started Doing This in the First Place

Denver got there first, in 2019, after a grassroots campaign that nobody outside Colorado expected to succeed. Oakland followed a month later with a broader resolution covering all entheogenic plants and fungi. Santa Cruz made three. Within a few years, the list grew to include Washington D.C., several Massachusetts towns, Detroit, and others — and Oregon voters went further still, approving regulated therapeutic psilocybin use statewide.

The arguments driving these votes tend to cluster around three points. First, there's the medical research — and there's now a serious amount of it. Johns Hopkins, Imperial College London, NYU, and others have published studies showing meaningful results for treatment-resistant depression, end-of-life anxiety, smoking cessation, and alcohol use disorder. A 2017 study in Nature Scientific Reports found nearly half of patients with treatment-resistant depression showed positive responses five weeks after psilocybin sessions. Numbers like that get policymakers' attention in a way that anecdotal testimony doesn't.

Second, there's the cultural lineage argument. Ayahuasca has been part of Amazonian healing for generations. Peyote is sacrament in the Native American Church. Psilocybin mushrooms appear in Mesoamerican religious practice going back centuries. Framing prohibition as a relatively recent and culturally narrow imposition makes the policy easier to unwind.

Third — and this is the one that resonates most with readers I've spoken to — there's the addiction question. Conventional treatment for addiction works for some people and fails badly for others. Plant medicine for addiction recovery, particularly ibogaine for opioid dependence and ayahuasca for various substance disorders, has produced results striking enough that even cautious clinicians are paying attention.

What Decriminalization Doesn't Solve If You're Considering a Retreat

Here's where I want to slow down, because the news cycle around decriminalization tends to imply more than it delivers for the person actually weighing a retreat.

Decriminalization at the city level changes nothing about your federal risk if you bring substances across borders or transport them between states. It does nothing for the safety of the ceremony you'd actually attend — that depends entirely on the facilitators, the setting, your preparation, and your own medical and psychological readiness. And it does not create a regulated marketplace where you can verify quality or training. In the cities that have decriminalized, you still can't walk into a storefront and book a sanctioned ayahuasca ceremony the way you can in Peru or Costa Rica.

For most people serious about a psychedelic retreat for addiction, depression, or trauma work, the realistic options remain:

• Travel to a country where ayahuasca is legal or culturally protected — Peru, Brazil, Costa Rica, the Netherlands for psilocybin truffles, Mexico for psilocybin and ibogaine.
• Look at Oregon's regulated psilocybin services, which operate under state licensure with trained facilitators.
• Consider clinical trials, which still accept participants for specific conditions at research institutions.

None of these are casual decisions. Each carries its own due diligence — facilitator credentials, medical screening (some SSRIs, MAOIs, and heart conditions are genuinely dangerous with ayahuasca), the ethical record of the retreat center, and what the integration support looks like in the weeks after you come home. The ceremony itself is maybe a third of the work. The preparation and the integration are the rest.

How to Read the Trend Without Getting Ahead of It

The temptation, when you see headlines like Santa Cruz's, is to assume the dam is breaking. It isn't, quite. What's happening is more interesting and more gradual: a steady accumulation of municipal and state-level decisions, combined with FDA breakthrough therapy designations for psilocybin and MDMA, that together signal a slow normalization of psychedelic-assisted therapy as a clinical category.

For someone researching a retreat right now, this trend matters for a few practical reasons. Quality is improving as the stigma lifts and more experienced facilitators come out of the shadows. Medical screening protocols are getting more rigorous. Integration services — therapists, coaches, peer groups who specifically work with people coming home from psychedelic experiences — are easier to find than they were five years ago.

It also means more people in your life may have already done this, which makes the conversation less awkward. Asking a friend who attended a ceremony two years ago what they wish they'd known is probably the single most useful research step you can take, after honest medical screening.

What Actually Matters When Choosing a Retreat

If the Santa Cruz vote nudged you toward looking more seriously, here's the short version of what I'd suggest paying attention to — gathered from too many conversations with people who got it right and people who got it wrong:

1. Facilitator lineage and experience. How long have they been working with this medicine? Who trained them? Are they part of a tradition or improvising? Both can work — but you should know which you're walking into.
2. Medical screening. A serious retreat will ask detailed questions about medications, cardiovascular health, and psychiatric history before they take your deposit. If they don't, that's the red flag.
3. Group size and staff ratio. Twenty participants and two facilitators is not a healing container. It's a logistical exercise.
4. Integration support. What happens after the last ceremony? Do they offer follow-up calls, integration circles, referrals? The first month back is where the real work either happens or doesn't.
5. Honest cost transparency. A weeklong ayahuasca retreat typically runs somewhere between $1,500 and $4,500 depending on location and inclusions. If a price feels suspiciously low, ask what's missing. If it feels suspiciously high, ask what justifies it.

Plant medicine isn't a guaranteed fix for addiction or depression, and any retreat that promises otherwise should make you nervous. What it can do — when the setting is sound and you've done your part — is open a window onto patterns that have been running your life from below. Whether you can keep that window open afterward depends on the work you do once the ceremony ends.

If something here has nudged you to look more seriously at the options, a range of curated ayahuasca and psilocybin retreats from facilitators around the world can be browsed on our marketplace here. Read carefully, ask hard questions, and take your time — the right retreat will still be there next month.